Browse > Article

A Case Report of HBeAg Seroconversion in Chronic Viral Hepatitis B  

Choi, Eun-sol (Dept. of Clinical Korean Medicine, Graduate School, Kyung Hee University)
Kim, Ha-yeon (Dept. of Clinical Korean Medicine, Graduate School, Kyung Hee University)
Bae, Jung-han (Dept. of Clinical Korean Medicine, Graduate School, Kyung Hee University)
Jang, Eun-gyeong (Dept. of Clinical Korean Medicine, Graduate School, Kyung Hee University)
Kim, Young-chul (Dept. of Clinical Korean Medicine, Graduate School, Kyung Hee University)
Lee, Jang-hoon (Dept. of Clinical Korean Medicine, Graduate School, Kyung Hee University)
Publication Information
The Journal of Internal Korean Medicine / v.37, no.3, 2016 , pp. 529-538 More about this Journal
Abstract
Objectives: The purpose of this case study is to report the efficacy and safety of treatment with Korean medicine of a patient with HBeAg-positive chronic viral hepatitis B.Methods: The patient took Korean medicine (mainly Injinchunggan-tang-gamibang) from July 20th, 2010, to March 14th, 2016, without any antiviral or interferon therapy. Changes to laboratory records, abdomen ultrasonography, and clinical symptoms were reviewed.Results: The laboratory records showed that AST, ALT, and HBV DNA had decreased to normal ranges, and HBeAg showed seroconversion. Clinical symptoms also improved after taking Korean medicine.Conclusion: The results suggest that treatment with Korean medicine and without antiviral or interferon therapy could be effective for HBeAg-positive chronic hepatitis B.
Keywords
chronic viral hepatitis B; hepatitis B virus (HBV); HBeAg-positive; HBeAg seroconversion; Injinchunggan-tang-gamibang; Korean medicine;
Citations & Related Records
Times Cited By KSCI : 6  (Citation Analysis)
연도 인용수 순위
1 Park CH, Lee SM, Kim TO, Kim DU, Jung WJ, Kim GH, et al. Treatment of solitary extramedullary plasmacytoma of the stomach with endoscopic submucosal dissection. Gut Liver 2009;3:334-7.   DOI
2 Song IS, Kim CY. Seasonal and annual variations on occurrence of HBsAg and acquisition of anti-HBs in Korea. Korean J Intern Med 1979;22:1007-15.
3 Korea Centers for Disease Control and Prevention. 2006 Disease Control White Paper. Korea Centers for Disease Control and Prevention. 2007;144.
4 Lee BS, Cho YK, Jeong SH, Lee JH, Lee D, Park NH, et al. Nationwide seroepidemiology of hepatitis B virus infection in South Korea in 2009 emphasizes the coexistence of HBsAg and anti-HBs. J Med Virol 2013;85:1327-33.   DOI
5 Ministry of Helalth & Welfare KCfDCaP. The Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV), 2010. Health Examination. Ministry of Helalth & Welfare 2012.
6 Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol 2009;15(Suppl 6):S13-S24.   DOI
7 Cheon JH, Park JW, Park KW, Kim YI, Kim SH, Lee WJ, et al. The clinical report of 1,078 cases of hepatocellular carcinomas: National Cancer Center experience. Korean J Hepatol 2004;10:288-97.
8 Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS; Organizing Committee of Japan-Korea Liver Symposium. Epidemiology of hepatocellular carcinoma in Japan and Korea. Oncology 2008;75(Suppl 1):13-6.   DOI
9 Bae SH, Yoon SK, Jang JW, Kim CW, Nam SW, Choi JY, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 2005;20:816-20.   DOI
10 Kim H, Jee YM, Song BC, Shin JW, Yang SH, Mun HS, et al. Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology 2007;50:52-7.   DOI
11 Lee JM, Ahn SH, Chang HY, Shin JE, Kim DY, Sim MK, et al. Reappraisal of HBV genotypes and clinical significance in Koreans using MALDI-TOF mass spectrometry. Korean J Hepatol 2004;10:260-70.
12 Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, et al Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007;133:1452-7.   DOI
13 The Korean Association for the Study of the Liver. 2015 Chronic Hepatitis B Clinical Practive Guideline. Seoul: Publishing & Printing Co. Jin; 2015, p. 32-72.
14 Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44.   DOI
15 Manns MP, Akarca US, Chang TT, Sievert W, Yoon SK, Tsai N, et al. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf 2012;11:361-8.   DOI
16 Koteiche HA, Reeves MD, McHaourab HS. Structure of the substrate binding pocket of the multidrug transporter EmrE: site-directed spin labeling of transmembrane segment 1. Biochemistry 2003;42:6099-105.   DOI
17 Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008;22:99-103.   DOI
18 Hong JW, et al. Study of Korean Medicine Liver System. 6th edition. Seoul: Publishing & Printing Co. Nado; 2015, p. 65-138, 262-305.
19 Kang KT, Lee JH, Woo HJ. The Effect of Inchinchunggantang-derivative on Mouse Virus Hepatitis(MHV-2M) and Water Immersion Stress. Journal of Kyung Hee University Graduate School 1997;20(2):133-50.
20 Park YJ, Kim YC, Lee JH, Woo HJ. The Effect of Injinchunggantang-derivative on Proliferation of Hepatocyte. J Korean Med 1998;19(1):145-64.
21 Hong SH, Lee JH, Woo HJ. The Effects of Injinchunggantang-derivative on Cell Viability, Cell Cycle Progression and Apoptosis of Hepatocytes. J Korean Med 1998;19(2):337-72.
22 Ko H, Lee JH, Woo HJ. The Effects of 5 kinds of Injinsaryung-San fractions on Cell Viablity, Cell Cycle Progression and Fas-mediated Apoptosis of HepG2 Cells. J Korean Med 2000;21(3):174-85.
23 Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-82.   DOI
24 Lee JH, Lee JH, Woo HJ. Effects of Five Fractions of Artemisia capillaris THUNB on TGFβ1-induced Apotosis in HepG2 Cells. J Korean Med 2000;20(1):53-61.
25 Shin SM, Kim YC, Lee JH, Woo HJ. Effect of Injin Fraction on Hepatic Fibrosis induced by TGF-β1. J Korean Med 2001;22(3):141-55.
26 Sim JG, Seo JK, Suh SJ. Prevalence and its changes of hepatitis B viral markers from 1988 to 1993 in Korean children. J Korean Pediatr 1995;38:1535-9.
27 Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72.
28 Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist 2011;4:55-64.
29 Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14.   DOI
30 Manns MP, Akarca US, Chang TT, Sievert W, Yoon SK, Tsai N, et al. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf 2012;11:361-8.   DOI
31 Jang EG, Kim YC, Woo HJ, Lee JH. The Effects of Injincheonggan-tang on Two Patients with HBeAg-Negative Chronic Hepatitis B : Case Report. J Korean Med 2014;35(2):69-78.   DOI
32 Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.   DOI
33 YJ Jung, JH Lee, SH Kim, CW Kim, JE Lee, YC Kim, HJ Woo. Five Cases of Patients Treated with Injinchunggan-tang for Liver Cirrhosis and Chronic Hepatitis B. Korean J Orient Int Med 2006;27(4):1014-26.
34 Kim CG. Study on the Maternal Serum Alpha-Fetoprotein During Pregnancy. Obstetrics & Gynecology Science 1986;29(9):1240-55.
35 Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86.   DOI
36 Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522-7.   DOI